[Pain management: health economics and quality of life considerations].
Pain represents a major clinical, social and economic problem, with estimates of its prevalence ranging from 8% to more than 60%, depending on the population. The impact of pain on economies is enormous, with the cost of back pain alone equivalent to more than one-fifth of one country's total health expenditure and 1.5% of its annual gross domestic product, while in another it represents three times the total cost of all types of cancer. However, decision makers have tended to concentrate their attention on one very minor component of the cost burden, namely prescription costs, which, in the case of back pain, represent 1% of the total cost burden. In addition to its economic impact, chronic pain is probably one of the diseases with the greatest negative impact on quality of life. For example, the quality of life for those with migraine had been shown to be at best equal to that for people with arthritis, asthma, diabetes mellitus or depression. The burden that pain imposes on individuals and the enormous costs that society has to bear as a result clearly demonstrate the need for collective thinking in the decision-making process. A broad, strategic perspective--based on evidence relating to effectiveness (including tolerability), efficiency and equity--is required in determining issues relating to the provision of services and resource allocation. In this regard, it is clear that paracetamol (acetaminophen) is effective in securing an analgesic effect; it has a good tolerability profile and is relatively cheap, in terms of both drug acquisition costs and its overall cost profile. Pain management strategies based on collective thinking should therefore place great reliance on paracetamol as an initial therapy in maximising pain relief and minimising cost and the impact of adverse effects.
Phillips
Ceri J
CJ
Centre d'Etudes de Politique et d'Economie de la Santé, Université de Swansea, Swansea, Pays de Galles, GB. c.j.phillips@swan.ac.uk
D000082:Acetaminophen / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D018712:Analgesics, Non-Narcotic / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D003363:Cost Control; D017281:Cost of Illness; D016527:Drug Costs / Q000706:statistics & numerical data*; D006801:Humans; D010146:Pain / Q000188:drug therapy* / Q000191:economics*; D011788:Quality of Life; D040841:Resource Allocation
D018712:Analgesics, Non-Narcotic; D000082:Acetaminophen